Cassava Sciences, Inc. (NASDAQ:FLNA – Get Free Report) CEO Richard Barry bought 100,000 shares of Cassava Sciences stock in a transaction that occurred on Wednesday, September 30th. The stock was bought at an average cost of $0.92 per share, with a total value of $92,000.00. Following the completion of the purchase, the chief executive officer owned 1,337,964 shares in the company, valued at approximately $1,230,926.88. This trade represents a 8.08% increase in their position. The acquisition was disclosed in a filing with the SEC, which is accessible through this link.
Richard Barry also recently made the following trade(s):
- On Tuesday, September 29th, Richard Barry acquired 206,813 shares of Cassava Sciences stock. The shares were purchased at an average price of $0.90 per share, with a total value of $186,131.70.
- On Monday, September 28th, Richard Barry purchased 93,091 shares of Cassava Sciences stock. The shares were acquired at an average cost of $0.84 per share, with a total value of $78,196.44.
Cassava Sciences Trading Down 4.2%
Cassava Sciences stock opened at $0.89 on Thursday. The company has a market cap of $42.80 million, a P/E ratio of -1.02 and a beta of -0.69. The company has a fifty day simple moving average of $0.88 and a 200 day simple moving average of $1.26. Cassava Sciences, Inc. has a 1-year low of $0.67 and a 1-year high of $4.98.
Hedge Funds Weigh In On Cassava Sciences
An institutional investor recently raised its position in Cassava Sciences stock. Caitong International Asset Management Co. Ltd boosted its holdings in Cassava Sciences, Inc. (NASDAQ:FLNA – Free Report) by 465.5% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 13,606 shares of the company’s stock after buying an additional 11,200 shares during the quarter. Caitong International Asset Management Co. Ltd’s holdings in Cassava Sciences were worth $27,000 at the end of the most recent reporting period. Institutional investors own 38.05% of the company’s stock.
Wall Street Analyst Weigh In
A number of equities research analysts recently weighed in on the company. Weiss Ratings upgraded Cassava Sciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, September 22nd. Wall Street Zen cut Cassava Sciences from a “hold” rating to a “sell” rating in a research note on Saturday, June 6th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Cassava Sciences currently has a consensus rating of “Hold” and a consensus target price of $5.00.
View Our Latest Analysis on FLNA
Cassava Sciences Company Profile
Cassava Sciences, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for neurodegenerative diseases. The company’s research has centered on simufilam, an investigational oral therapy designed to target an altered form of the scaffolding protein filamin A that Cassava has linked to Alzheimer’s disease pathology.
Simufilam has been evaluated in clinical studies involving patients with Alzheimer’s disease, but it is an investigational product and is not approved for commercial use.
Featured Stories
- Five stocks we like better than Cassava Sciences
- Cleared for Takeoff: AAR Corp. Expands Its Aerospace Aftermarket Reach
- L3Harris’ $6 Billion THAAD Win Comes at a Crucial Moment for the Stock
- Boeing’s Fighter Victory Opens the Door to Decades of Defense Revenue
- Deutsche Bank Makes a Contrarian Call on Netflix—What Does It Mean for Investors?
Receive News & Ratings for Cassava Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cassava Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
